Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Dec;42(4):217-24.
doi: 10.4143/crt.2010.42.4.217. Epub 2010 Dec 31.

Clinicopathologic features of metachronous or synchronous gastric cancer patients with three or more primary sites

Joo Hoon Kim  1 , Sun Young Rha, Chan Kim, Gun Min Kim, Sang Hyun Yoon, Ki Hyang Kim, Min Jae Kim, Joong Bae Ahn, Hyun Cheol Chung, Jae Kyung Roh, Hyo Song Kim
Affiliations

Clinicopathologic features of metachronous or synchronous gastric cancer patients with three or more primary sites

Joo Hoon Kim et al. Cancer Res Treat. 2010 Dec.

Abstract

Purpose: We investigated the clinicopathologic information of patients with gastric cancer with multiple primary cancers (GC-MPC) of three or more sites.

Materials and methods: Between 1995 and 2009, 105,908 patients were diagnosed with malignancy at Severance Hospital, Yonsei University Health System. Of these, 113 (0.1%) patients with MPC of three or more sites were registered, and 41 (36.3%) of these were GC-MPC. We retrospectively reviewed the clinical data and overall survival using the medical records of these 41 GC-MPC patients. We defined synchronous cancers as those occurring within 6 months of the first primary cancer, while metachronous cancers were defined as those occurring more than 6 months later.

Results: Patients with metachronous GC-MPC were more likely to be female (p=0.003) and young than patients with synchronous GC-MPC (p=0.013). The most common cancer sites for metachronous GC-MPC patients were the colorectum, thyroid, lung, kidney and breast, while those for synchronous GC-MPC were the head and neck, esophagus, lung, and kidney. Metachronous GC-MPC demonstrated significantly better overall survival than synchronous GC-MPC, with median overall survival durations of 4.7 and 14.8 years, respectively, and 10-year overall survival rates of 48.2% and 80.7%, respectively (p<0.001).

Conclusion: Multiplicity of primary malignancies itself does not seem to indicate a poor prognosis. The early detection of additional primary malignancies will enable proper management with curative intent.

Keywords: Multiple primary; Neoplasms; Stomach neoplasms.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Site distribution of gastric cancer with multiple primary cancer (GC-MPC) of whole 41 patients (A) and metachronous/synchronous distribution (B).
Fig. 2
Fig. 2
Site distribution according to gender differences (A), site distribution of metachronous multiple primary cancers (MPC) (B) and synchronous MPC (C) based on gender differences.
Fig. 3
Fig. 3
Ten year overall survival difference between synchronous and metachronous gastric cancer with multiple primary cancer (GC-MPC).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Otsuji E, Yamaguchi T, Sawai K, Hagiwara A, Taniguchi H, Takahashi T. Recent advances in surgical treatment have improved the survival of patients with gastric carcinoma. Cancer. 1998;82:1233–1237. - PubMed
    1. Ikeda Y, Mori M, Koyanagi N, Wada H, Hayashi H, Tsugawa K, et al. Features of early gastric cancer detected by modern diagnostic technique. J Clin Gastroenterol. 1998;27:60–62. - PubMed
    1. Maehara Y, Okuyama T, Moriguchi S, Orita H, Kusumoto H, Korenaga D, et al. Prophylactic lymph node dissection in patients with advanced gastric cancer promotes increased survival time. Cancer. 1992;70:392–395. - PubMed
    1. Hiyama T, Hanai A, Fujimoto I. Second primary cancer after diagnosis of stomach cancer in Osaka, Japan. Jpn J Cancer Res. 1991;82:762–770. - PMC - PubMed
    1. Furukawa H, Hiratsuka M, Iwanaga T, Imaoka S, Kabuto T, Ishikawa O, et al. Treatments for second malignancies after gastrectomy for stomach cancer. Hepatogastroenterology. 1996;43:194–198. - PubMed

LinkOut - more resources